Thirty-six 6(7)-substituted-3-methyl- or 3-halogenomethyl-2-phenylthio-phenylsulphonyl-chloro-quinoxaline 1,4-dioxides belonging to series 3-6 were synthesised and submitted to a preliminary in vitro evaluation for antimycobacterial, anticandida and antibacterial activities. Antitubercular screening showed a generally good activity of 3-methyl-2-phenylthioquinoxaline 1,4-dioxides (3d,e,h-j) against Mycobacterium tuberculosis, and exhibited MIC between 0.39 and 0.78 mug mL(-1) (rifampicin MIC = 0.25 mug mL(-1)), whereas in compounds 4d,e, 5a,b,d,e,l and 6b-e,j,l MIC ranged between 1.56 and 6.25 mug mL(-1). Results of the antibacterial and anticandida screening showed that 6e and 6l exhibited MIC = 0.4 and 1.9 mug mL(-1), respectively, against Candida krusei (miconazole MIC = 0.9 mug mL(-1)), and 4i, 5b,d, 6e, MIC = 3.9 mug mL(-1) against Candida glabrata (miconazole MIC = 0.4 mug mL(-1)), while compounds 3d,l, 5e,l, and 6b,d,e,l showed MIC = 15.6 mug mL(-1) against Vibrio alginolyticus. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity / Carta, Antonio; Paglietti, G; RAHBAR NIKOOKAR, Me; Sanna, P; Sechi, Leonardo Antonio; Zanetti, Stefania Anna Lucia. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 37:(2002), pp. 355-366. [10.1016/S0223-5234(02)01346-6]

Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity

CARTA, Antonio;SECHI, Leonardo Antonio;ZANETTI, Stefania Anna Lucia
2002

Abstract

Thirty-six 6(7)-substituted-3-methyl- or 3-halogenomethyl-2-phenylthio-phenylsulphonyl-chloro-quinoxaline 1,4-dioxides belonging to series 3-6 were synthesised and submitted to a preliminary in vitro evaluation for antimycobacterial, anticandida and antibacterial activities. Antitubercular screening showed a generally good activity of 3-methyl-2-phenylthioquinoxaline 1,4-dioxides (3d,e,h-j) against Mycobacterium tuberculosis, and exhibited MIC between 0.39 and 0.78 mug mL(-1) (rifampicin MIC = 0.25 mug mL(-1)), whereas in compounds 4d,e, 5a,b,d,e,l and 6b-e,j,l MIC ranged between 1.56 and 6.25 mug mL(-1). Results of the antibacterial and anticandida screening showed that 6e and 6l exhibited MIC = 0.4 and 1.9 mug mL(-1), respectively, against Candida krusei (miconazole MIC = 0.9 mug mL(-1)), and 4i, 5b,d, 6e, MIC = 3.9 mug mL(-1) against Candida glabrata (miconazole MIC = 0.4 mug mL(-1)), while compounds 3d,l, 5e,l, and 6b,d,e,l showed MIC = 15.6 mug mL(-1) against Vibrio alginolyticus. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity / Carta, Antonio; Paglietti, G; RAHBAR NIKOOKAR, Me; Sanna, P; Sechi, Leonardo Antonio; Zanetti, Stefania Anna Lucia. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 37:(2002), pp. 355-366. [10.1016/S0223-5234(02)01346-6]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/58883
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 128
  • ???jsp.display-item.citation.isi??? 119
social impact